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Abstract
Coeliac disease is one of the best understood models of 
adaptive immunity in which a known dietary component 
triggers over-presentation of a known autoantigen in genetically-
predisposed individuals.  The dynamics of this gene-nutrient 
interaction and the mechanism responsible for accelerated 
programmed death of the enterocytes lining the upper small 
intestine are explored in order to generate insight into the large 
number of candidate pharmacological agents that may well aid 
or replace cumbersome dietary treatment in years to come.
Dr. Dicke kicks off to a good start
Research into the cause of coeliac disease (CD) was put 
on the right path by Dr. William Karell Dicke, Director of 
the Childrens’ Hospital in The Hague, Netherlands.  Dicke 
was impressed in 1932 by reports of a child whose diarrhoea 
recurred on repeated challenge with bread and rusks. During 
the Dutch winter of starvation of World War II, cereal rationing 
serendipitously cured many of Dr. Dicke’s coeliac patients.  By 
1953 Dicke1 had published a paper with J. H. Van de Kamer, a 
nutritional biochemist showing that the alcohol-soluble (gliadin) 
fraction of the water-insoluble (gluten) component of wheat was 
responsible for steatorrhoea in CD.  After some initial scepticism 
it became apparent that the flat appearance of duodenal biopsies, 
initially ascribed to a biopsy forceps-related crush artifact was 
the result of a gross immunological attack on the enterocytes 
lining the intestinal villi.  For many years the exact autoantigen 
remained elusive.  
Back to the drawing board
The earliest event in the pathogenesis of CD in now known 
to involve the binding of toxic but non immunogenic gliadin 
peptides on the enterocyte luminal membrane to the surface 
receptors of “zonulin”, a novel signaling protein that induces 
polymerization of actin microfilaments in the enterocyte 
cytoskeleton.2 These intracellular strands interact with the 
proteins of the intercellular “tight junctions” permitting 
paracellular passage of gliadin peptides into the lamina propria 
without subjecting them to the natural process of intracellular 
lysosomal degradation that would otherwise limit their 
antigenicity (Figure 1).
Certain peptides released by the luminal digestion of gluten 
are resistant to the usual further digestion by peptidases located 
in enterocyte brush borders.  Some of these peptides (e.g. the 
poorly digested 33 amino acids peptide (56-89)) contain several 
immunostimulant sequences which may elicit a damaging 
immune response in the lamina propria.3  Another possible 
scenario is that minor amounts of gluten peptides cross the 
enterocyte by specific transcytotic mechanisms where they 
may be partly digested by cathepsins to release immunogenic 
fragments (Figure 1).4
Whatever their mode of transport, experiments show 
that immunogenic peptides gain access to dendritic cells in 
the intestinal lamina propria.  These professional antigen-
presenting cells (APC) stimulate T-helper cells to induce 
apoptosis (programmed cell death) of enterocytes and also elicit 
a damaging humoral response.  The race is now on to identify 
which dietary peptides are truly immunogenic in the hope of 
finding the epitopes which fit into the antigen binding groove 
of APCs.  Various peptides, obtained by tryptic digestion of 
A-gliadin are now under intense scrutiny by food chemists.
Genetically driven warfare: 
enter tissue transglutaminase
Coeliac disease is one of the best understood models of 
adaptive immunity against a known trigger that is determined 
by variability in primitive antigen presenting molecules (MHC 
glycoproteins) encoded by the HLA locus of the MHC genes on 
chromosome 6.  Coeliac disease develops almost exclusively in 
patients who carry the HLA class II molecules DQ2 or DQ8.5
Tissue tranglutaminase (tTG) has emerged as the culprit 
autoantigen responsible for chronicity in coeliac disease.6 
Antibodies against tTG can be detected by a number of 
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Figure 1: Sequence by which gluten peptides lead to intestinal epithelial damage
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commercially available serologic kits. tTG is found in the 
enterocyte brush border, fibroblasts and inflammatory cells of 
the lamina propria and beyond the intestine in skin, kidney and 
lung cells. tTG maintains the integrity of the healthy intestine by 
cross-linking several matrix proteins in the epithelial basement 
membrane. The cross-linking of glutaminase-containing 
sequences such as gliadin peptides with lysine-containing 
peptides which abound in matrix collagen may enhance the 
immunogenicity of gliadin by generating neo-epitopes which 
persist in the basement membrane.7  
Inflammation and low pH favour deamidation of gliadin 
rather then its cross linking.  Deamidation provides negatively 
charged peptides which have a higher affinity for the antigen 
binding site of HLA DQ2 and DQ8 molecules expressed on 
the surface of APCs such as the dendritic cells of the intestinal 
epithelium.8 Dendritic cells internalize, partly degrade and 
selectively process gliadin peptide fragments before re-
expressing them bound to the MHC group on their plasma 
membrane. Alfa-2 gliadin contains a 33 amino acids digestion 
resistant peptide containing three stretches of a conserved motif 
that is found in many immunodominant gluten peptides.  
Dendritic cells then migrate through the lamina propria 
and mesenteric lymph node where they associate freely and 
promisciously with CD4+ and T-Helper lymphocytes (TH). 
Meanwhile the gliadin derived peptides are internalized by 
dendritic cells into endosomes  where they are partially digested. 
Only a few of the resulting peptide fragments will fit the antigen 
binding groove of MHC class II molecules synthesised in the 
endoplasmic reticulum of the APC and encoded by highly 
polymorphic HLA DQ2 and DQ8 genes which determine disease 
susceptibility.  When MHC bound peptides on the surface on 
the APC are recognized by T cell receptors (TCR) on Class 
II restricted TH cells, the number of TH cells triggered will 
determine whether the reaction stops here (immunological 
tolerance) or progresses to cell-mediated immune damage.
Intercellular adhesion molecules such as ICAM1 help to 
approximate the antigen to the TCR but bound antigen will not 
trigger the T cell unless co-stimulatory molecules are present. 
Absence of costimulation is one of nature’s way of promoting 
immunological tolerance.  After triggering, TH cells produce 
a predominantly TH1 response by secreting the cytokines 
IL2, TNFa and IFNγ. These cytokines which specialize in cell-
mediated cytotoxicity allow mesenchymal cells in the lamina 
propria to release destructive matrix metallo-proteinases (MMP) 
that greatly accelerate the apoplosis or programmed cell death 
of villous enterocytes. Other TH cells release TH2 cytokines 
that induce proliferative and humoral responses, stimulating B 
lymphocytes to produce antibodies against gluten and tTG that 
are detectable in the circulation (Figure 1).
Enter the intra epithelial lymphocytes (IELs)
Cytotoxicity in the lamina propria is complemented by 
a unique population of lymphocytes called intra-epithelial 
lymphocytes (IEL) that proliferate between the enterocytes on 
APC
Antigen presenting cells are bone marrow-derived cells 
that hold antigens for presentation to T lymphocytes.
Apoptosis
A genetically determined or triggered process of 
programmed cell death, or “cell suicide”; which removes 
harmful or aging cells from the body without tissue 
damage.
CD4+
A marker carried by helper T cells which help orchestrate 
the antibody response in contrast to the other cluster of 
differentiation (CD) markers on cytotoxic or suppressor T 
cells which are involved in cell-mediated immunity.
HLA
Human leucocyte antigens are genetically determined 
antigens on the surface of cell membranes that serve to 
identify a cell as self or nonself.
IEL
Intraepithelial lymphocytes are T lymphocytes that are 
situated among the enterocytes lining the intestinal 
villous. 
Immunodominant
Possessing an area (called an epitope) on the surface 
of an antigen capable of stimulating a specific immune 
response.
Motif
A short, highly conserved, often repetitive, region in a 
protein sequence.
MHC
Complex of  genes coding for a large family of cell-surface 
proteins that bind peptide fragments and present them 
to T-lymphocytes to induce an imamune response.  MHC 
class I molecules exist on all cells and hold and present 
foreign antigens to CD8 cytotoxic T lymphocytes if the 
cell is infected e.g. by a  virus. MHC class II molecules are 
found on APCs and display antigen to activate CD4+ cells.
TH response
An acquired T cell response characterized by high 
cytotoxic T lymphocyte activity relative to the amount of 
antibody production. The TH1 response is promoted by 
CD4 “TH1” subset of T-helper cells.
TH2 response
An acquired T cell response characterized by high 
antibody production relative to the amount of cytotoxic 
T lymphocyte activity. The TH2 response is promoted by 
CD4 “TH2” T-helper cells. 
Table 1: 
Glossary of immunological terms and abbreviations 
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their basolateral surface.  IEL’s express the marker CD8 and 
are more likely to express the g/d TCR then CD4+ T cells which 
usually carry the a/b TCR.  IELs recognize a narrow spectrum 
of antigen in the context of an MHC class 1 molecule.  Their 
function is to tackle and kill, via IFNγ production and apoptosis 
any enterocytes that express abnormal cell proteins on their 
damaged surface.  Their CD45RO phenotype indicates that they 
are also memory cells capable of rapid enterocyte  destruction.9 
IELs are probably the progeny of MHC class I restricted T cells 
which were “educated” in the lymphoid tissue of the ileal Peyer’s 
patches by antigen-sampling “M cells” before circulation and 
homing to the enterocytes covering the intestinal villous.10
The murder weapons revealed
Cytotoxic cells kill enterocytes in many ways.  They may 
degranulate releasing serum proteases called “granzymes” and 
the subunits of membrane drilling proteins called “perforins”11 
which are endocytosed by enterocytes.  Once inside their 
innocent victims perforins self-assemble releasing powerful 
granzymes into the cytoplasm. Further triggering of apoptosis 
results from IFN secretion and the expression of Fas ligand 
which binds to enterocyte membranes.  This irreversible “death 
sequence” in doomed enterocytes usually starts with receptor-
mediated elevations in intracellular calcium which activates 
destructive calcium-dependent enzymes such as capsases and 
endonucleases.  
The battle ground from above: 
a histopathologist’s perspective
The duodenum appears to take the brunt of the immune 
assault while the jejunum and ileum show less severe histological 
damage.  This is fortuitous as endoscopic duodenal biopsies are 
sensitive markers of disease activity even though they do not 
indicate the extent of small bowel damage.  Duodenal histology 
provides a mere single-frame glimpse of a process of accelerated 
enterocyte apoptosis.  Marsh12 had described four phases which 
are thought to occur consecutively.  The earliest (Marsh I) lesion 
consisting of increased IELs (< 30 per 100 enterocytes) is seen 
in patients suffering from Dermatitis Herpertiformis. The base 
of each villous is surrounded by 4-10 crypts of Lieberkuhn which 
contain rapidly prolferating enterocyte progenitors. Crypt cells 
move 1-2 cell positions per hour in the enterocyte monolayer up 
the side of the villous reaching the villous tip in about 5 days. 
The mucosa responds to apoptosis by hyperplasia and branching 
of the crypts which compensate for accelerated shedding of 
enterocytes at the villous tips (Marsh II). Some patients will 
“decompensate” with partial (Marsh III) or complete (Marsh IV) 
villous atrophy.  Tumour necrosis factor activated by TH1 cells 
triggers intestinal fibroblasts to release matrix metalloproteins 
which stimulate mesenchymal migration and proliferation 
increasing the bulk of the lamina propria and causing further 
deepening of the crypts and effacement of villi.
A Marsh III lesion with a crypt-to-villous height ratio above 
1.0 is the gold standard for diagnosing coeliac disease. Biopsy 
reports should be read in the context of serological tests since 
small intestinal bacterial overgrowth, giardiasis, and cow’s 
milk protein allergy can cause villous atrophy.  Marsh I and 
II biopsies present a diagnostic dilemma and patients should 
be warned of this limitation before proceeding to endoscopic 
biopsy.  Wahab etal13 demonstrated progression to Marsh III 
lesions in only 12 of 38 patients with Marsh I biopsies after an 
8 week gluten challenge. All 12 patients experienced symptom 
relief on a subsequent gluten free diet (GFD) but histological 
response was variable. Failure of symptoms to respond to a 
gluten challenge predicted absence of histological improvement 
on a GFD in many cases. Whether GFD prevents complications 
in histological non-responders is not known.  
Many patients with latent CD exhibit a loss of the decrescendo 
pattern of IELs which are usually more crowded at the base of 
the villous that at its apex in normal individuals.14 However up 
to 25% of patients with a relative increase of IELs in the villous 
distal sides and tips do not develop coeliac disease on follow up. 
The diagnostic value of this finding is therefore limited.
Digestion disarmed and dismantled
The immune attack on enterocytes grossly reduces 
absorptive surface area and deprives the intestine of precious 
disaccharidases located in the microvillous brush border. 
Increased intestinal permeability makes the small intestine 
more susceptible to the osmotic pull of undigested disaccharides 
which manifests as reducing substances in the stool.  Further 
osmotic diarrhoea results from unabsorbed fatty acids which 
also ferment in the colon to produce excess hydrogen and 
methane and volatile fatty acids causing a distended abdomen, 
explosive steathorrea and perianal burning in children.  Rarely 
a microscopic colitis and/or an autoimmune pancreatitis add 
to the digestive chaos.   
Beyond the gut: the mysteries deepen
Many extraintestinal manifestations of CD are poorly 
understood and probably harbour important clues as to its 
pathogenesis. CD osteopathy (osteomalacia + osteopenia) 
has been traditionally attributed to malabsorbtion of dietary 
calcium complicated by negative calcium balance and secondary 
hyperparathyroidism.  tTG is also present in bone where it 
promotes the cross-linking of a non-collagenous bone protein 
substrate called osteocalcin greatly increasing its rate of 
incorporation into growing bone collagen.  Immunofluorescent 
studies on sera pf CD patients showed high titres of antibone 
antibodies (with bone tTG as the likely autoantigen) which bind 
to areas of active mineralization in foetal rat tibia.15 An immune 
attack on tTG causing reduced collagen incorporation into 
growing bone would therefore also explain CD osteopathy.
tTG is also implicated in many cases of sporadic atoxia 
without features of multiple system atrophy i.e. autonomic and 
pyramidal features.  These so called “gluten ataxias”, which often 
feature cerebellar atrophy on MRI and a silent sensory-motor 
axonal neuropathy on EMG often show deposition of IgA tTG 
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in the jejunum and brain blood vessels as well as high litres of 
circulating antigliadin antibodies. As in dermatitis herpeliformis 
where the immune attack is directed toward epidermal tTG, 
jejunal biopsies may be misleadingly normal.
The possible role of tTG in the causation of Alzheimer’s 
disease (AD) and Huntington’s chorea are also very intriguing. 
CSF tTG is raised in many AD patients and tTG is up-regulated 
in the AD brain and localises to the microtubule “tau” protein 
with its characteristic neurofibrillary tangles.  It is not yet known 
whether excessive cross-linkage and consequent insolubility 
of tau may damage microtubule function by increasing its 
persistence.16
tTG is also elevated in the brain of many Huntington’s 
Disease (HD) patients who exhibit characteristic neuronal 
intranuclear and cytosolic inclusion bodies containing the 
mutant “Huntington protein.”  Again polyamination and 
excessive cross-linking of truncated forms of this mutant 
protein are being scrutinized as putative mechanism for neural 
damage.17
Conclusion
A better understanding of the way in which immunogenic 
peptides derived from gliadin are processed by enterocytes and 
modified by tissue transglutaminases in the intestine and other 
organs to enhance their presentation to the immune system as 
well as the cytokines, T cell subsets and humoral mechanisms 
involved in enterocyte apoptosis has provided numerous 
possibilities for dietary and pharmacological manipulation at 
various levels in the inflammatory cascade.  The quality of life 
of the coeliac disease patient may be improved by enzymatic or 
immunological therapies which may allow intestinal mucosal 
remission to be achieved with less stringent dietary gluten 
restriction making the coeliac diet more varied and palatable.  
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